NEA’s Ed Mathers talks biopharma investment trends and why it’s worth sticking around
It's safe to say Ed Mathers has accrued some industry know-how after 35 years in the biopharma industry — 15 of which have been spent on the investor side. So what's his take on today's high potential therapeutic areas?